Sneha Jagtap, Chandrakant Magdum, Rajesh Jagtap
Sneha Jagtap1*, Chandrakant Magdum2, Rajesh Jagtap1
1Annasaheb Dange College of B Pharmacy, Ashta, Sangli - 416301 Maharashtra, India.
2Rajarambapu College of Pharmacy, Kasegaon, Sangli - 415404 Maharashtra, India.
Volume - 14,
Issue - 1,
Year - 2021
The capability of novel solubilizer sepitrap 80 and sepitrap 4000 to enhance the solubility, dissolution was assessed in current investigation through the formation of simple physical mixture with a poorly aqueous soluble drug Flurbiprofen, phenylalkanoic acid derivative from non-steroidal anti-inflammatory drugs (NSAIDs).The physical mixtures were prepared in 1:1, 1:2 and 1:3 proportions with sepitrap 80 and sepitrap 4000 and characterized for saturation solubility, dissolution, and stability studies. The physicochemical properties of physical mixtures with solubilizer were confirmed by DSC, PXRD, and SEM. Saturation solubility was carried in order to determine solubility of drug in distilled water. The physical mixtures exhibited solubility of 261% and 369.87%with sepitrap 80 and sepitrap 4000. The dissolution rate and solubility were undoubtedly improved by physical mixtures as compared to model drug alone. Physical mixtures incorporated with sepitrap 4000 at 1:2 ratio proved better thansepitrap 80. Hence, the sepitrap could be exploited as a solubilizer to improve the solubility of Flurbiprofen.
Cite this article:
Sneha Jagtap, Chandrakant Magdum, Rajesh Jagtap. Ameliorated Solubility and Dissolution of Flurbiprofen using Solubilizer Sepitrap 80 and Sepitrap 4000. Research J. Pharm. and Tech. 2021; 14(1):21-27. doi: 10.5958/0974-360X.2021.00005.6
Sneha Jagtap, Chandrakant Magdum, Rajesh Jagtap. Ameliorated Solubility and Dissolution of Flurbiprofen using Solubilizer Sepitrap 80 and Sepitrap 4000. Research J. Pharm. and Tech. 2021; 14(1):21-27. doi: 10.5958/0974-360X.2021.00005.6 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-1-5
1. Davies N M. Clinical pharmacokinetics of Flurbiprofen and its enantiomers. Clin. Pharmacokinet. 1995; 28: 100-114.
2. Brogden RN, Heel RC, Speight TM, Avery GS. Flurbiprofen: A review of its pharmacological properties and therapeutic use in rheumatic diseases. Drugs. 1979; 18: 417-438.
3. Maroof K, Zafar F, Ali H, Naveed S. Flurbiprofen: a potent pain reliever. Journal of Bioequivalence and Bioavailability. 2015; 7(1): 056-058.
4. Anderson BD, Conradi RA. Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J. Pharm. Sci. 1985; 74: 815-820.
5. Veerareddy PR, Vemula SK. Formulation, evaluation and pharmacokinetics of colon targeted pulsatile system of flurbiprofen. J Drug Target. 2012; 20(8): 703-714.
6. Shrama D, Soni M, Kumae S, Gupat GD. Solubility enhancement-eminent role poorly soluble drugs. Research J. Pharm. and Tech. 2009; 2(2): 220-224.
7. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deli Rev. 2001; 46: 75-87.
8. Sneha Jagtap, Chandrakant Magdum, Dhanraj Jadge, Rajesh Jagtap. Solubility enhancement technique: A Review. J. Pharm. Sci. and Res. 2018; 10(9):2205-2211.
9. Jagtap SR, Magdum CS. Influence of Water-soluble polymers on Epalrestat ternary complexation by kneading. Research J. Pharm. and Tech. 2019; 12(8): 3602-3608.
10. Bhaskar D, Chella N, Sateesh KV, Rama RT. Solubility and dissolution enhancement of flurbiprofen by solid dispersion using hydrophilic carriers. Brazilian Journal of Pharmaceutical Sciences. 2017;53(4):1-10.
11. Koli S, Desai BG, Murthy P N, Sirisha VR. Solubility enhancement of Itraconazole by hypromellose formulted by solution-suspension layering. Research J. Pharm. and Tech. 2018; 11(11): 4850-4853.
12. Sanjeev Gubbi, Ravindra Jarag. Liquisolid Technique for Enhancement of Dissolution Properties of Bromhexine Hydrochloride. Research J. Pharm. and Tech. 2019; 2(2): 382-386.
13. Asija R, Patel P, Asija S. The liqusolid technique for enhancement of drug dissolution. Research J. Pharm. and Tech. 2012; 5(10): 4850-4853.
14. Ana RC. Duarte, Patrıcia C, Hermınio C. Catarina MM. Solubility of flurbiprofen in supercritical carbon dioxide. J. Chem. Eng. Data. 2004; 49:449-452.
15. Ping li, luweizhao. Solubilization of flurbiprofen in ph-surfactant solutions. Journal of Pharmaceutical Sciences, 2003; 92: 5.
16. Dong XL, Myo J H, Prabagar B, Yi D Y, Dong Hoon Oh, Jung Hyun Joe, Youngee Seo, Jong Oh Kim, Sang Man Park, Chul Soon Yong, Han-GC. Enhanced oral bioavailability of flurbiprofen by combined use of micelle solution and inclusion compound. Arch Pharm Res.2010; 33(1): 95-101.
17. Ahmed MA, Rhgigh AM, Shakeel F. Effects of surfactants on the crystal properties and dissolution behavior of Aspirin. Asian J. Research Chem. 2009; 2(2): 202-206.
18. Idrees MA, Rahman NU, Ahmad S, Ali MY, Ahmad I. Enhance transdermal delivery of flurbiprofen via microemulsions: Effects of different types of surfactants and cosurfactants, DARU Journal of Pharmaceutical Sciences. 2011; 19 (6): 433-439.
19. Hyung HB, So YK, Shin JR, Won SL, Ho-Joon Yang, Jung MH, Han GC, Yong RK, Chul SY. Enhanced solubility and bioavailability of flurbiprofen by cycloamylose. Arch Pharm Res.2011; 34(3): 391-397.
20. Patil A, Desai BG, Shivkumar HN, Purvang. Enhancement of Nateglinide solubility and dissolution. Research J. Pharm. and Tech. 2011; 4(7): 1159-1164.
21. Pandey S, Ujjal Kumar D, Bhoyar B, Patil A. Dissolution rate enhancement, In vitro investigation and of drug release kinetics of Flurbiprofen solid dispersion. Journal of Pharmaceutical research. 2013; 12(2): 72-79.
22. Patel H, Tiwari P, Patel J. Solid dispersion based tablets of poorly soluble drugs Flurbiprofen. American Journal of Pharm Tech Research. 2011; 1(1): 18-24.
23. Otra KA, Prameela RD. Kumar V. Formulation and evaluation of solid dispersions of Flurbiprofen for dissolution rate enhancement. J. Chem. Pharm. Res, 2011; 3(6):277-287.
24. Hasanain SM, Jinan MA, Maryam H. Alaayedi, MK. Obaiss SS, Mays M. Abdulmahdi L R, Hameed WA, Abbas WM. Formulation and evaluation of flurbiprofen solid dispersion. IJPPR. Human, 2016; 7 (3): 78-90.
25. Available at www.seppic.com
26. Kumar AM, Kulyadi GP, Mutalik S, Kulkarni VI, Tippavajhala VK. Application of hot melt extrusion for the solubility enhancement of a BCS class II drug. Research J. Pharm. and Tech. 2019; 12(8): 3751-3754.
27. Mitrabhanu M, Apte SS, Pavani A, Appadwedula VS. Solubility improvement of Lapatinib by novel techniques of solid dispersion. Research J. Pharm. and Tech. 2019; 12(4): 1664-1674.
28. Hajare AA, Kashid UT, Pavani W, Hajare PM. Enhancement of dissolution rate and formulation development of Efavirenz capsules employing solid dispersion method. Research J. Pharm. and Tech. 2013; 6(1): 112-117.
29. Jagtap RS, Doijad RC, Mohite SK. Adsorption of nifedipine on porous calcium silicate for enhancement of solubility and dissolution rate. Research J. Pharm. and Tech. 2019; 12(3): 1273-1279.
30. Yadav B, Tanwar YS, Mangal SP. Development and validation of spectrophotometric method for determination of flurbiprofen in bulk and formulation. International Journal of Pharmaceutical and Biological Archives. 2014; 5(4): 95 – 98.
31. Sajeev, C. Pravin R. Jadhav D, Ravi S, Saha RN. Determination of flurbiprofen in pharmaceutical formulations by UV spectrophotometry and liquid chromatography. Analytica Chimica Acta. 2002; 463: 207–217.
32. Varma MM, Pandi JK. Dissolution, solubility, XRD, and DSC Studies on Flurbiprofen-Nicotinamide Solid Dispersions. Drug Development and Industrial Pharmacy, 2005; 31:417–423.
33. Jagtap R, Doijad R, Mohite S. Enhancement of solubility and dissolution rate of class-II drug Nifedipine by using Novel Solubilizer sepitrap 80 and Sepitrap 4000; In vitro- In Vivo evaluation. Journal of Drug Delivery and Therapeutics. 2018; 8(5-s):293-300.
34. Ahmed BF, Joan Q, Elizabeth LL, Siok YC. An investigation into the factors governing the degree of dissolution enhancement of solid dispersion for poorly soluble drugs. Journal of Advances in Medical Research 2016; 1(4).
35. Verma MM, Pandi JK. Dissolution, solubility XRD, and DSC studies on Flurbiprofen-Nicotinamide solid dispersions. Drug Development and Industrial Pharmacy. 2005; 31:417-423.
36. Otagiri M, Imai T, Matumoto N, Uekama K. Improvements to some pharmaceutical properties of flurbiprofen by b- and g-cyclodextrin complexations. Acta Pharm. Suec. 1983; 20: 1–10.
37. Rhodes CT, Cartesan T. Drug Stability Principle and Procedure, 3rd ed, New York, 2001
38. International conference on harmonization (ICH) harmonized tripartite guideline for stability testing of new drugs substances and products Q1A (R2) aug-2003. Q1 (R2) Mar 2004.
39. Yi T, Wan J, Xu H. A new solid self-micro emulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water-soluble drugs. Eur J Pharm Biopharm 2008; 70: 439-444.
40. Atsushi M, TadakazuT, Yoshiharu M. Evaluation of the bioavailability of flurbiprofen and its b-cyclodextrin inclusion complex in four different doses upon oral administration to rats. European Journal of Pharmaceutics and Biopharmaceutics 2004; 58: 667–671.
41. Chadubhai PR, Abraham S, Srinivasan B, Madhavan V. Compression coated tablets of Flurbiprofen: A chronotherapeutic approach. Journal of Scientific and Innovative Research. 2013; 2(5):914-926.